Unknown

Dataset Information

0

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.


ABSTRACT: Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgG?) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.

SUBMITTER: Friend R 

PROVIDER: S-EPMC5367738 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Friend Reed R   Bhutani Manisha M   Voorhees Peter M PM   Usmani Saad Z SZ  

Drug design, development and therapy 20170320


Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations. ...[more]

Similar Datasets

| S-EPMC5026292 | biostudies-literature
| S-EPMC6230619 | biostudies-other
| S-EPMC6774869 | biostudies-literature
| S-EPMC8116297 | biostudies-literature
| S-EPMC6205184 | biostudies-literature
| S-EPMC5841936 | biostudies-literature
| S-EPMC4438995 | biostudies-literature
| S-EPMC4946088 | biostudies-literature
| S-EPMC4959642 | biostudies-literature
| S-EPMC5533303 | biostudies-literature